Design, synthesis and structure of peptides and proteins news

<p>Ernest Giralt receives the diploma at La Marató ceremony</p>
2 Nov 2018

The project presented by Ernest Giralt (IRB Barcelona) and Jordi Vila (ISGLOBAL) has been awarded € 260,000.

Of the 214 projects that applied for funding, 36 were selected on the basis of the evaluation of 103 scientists.

This is the third time that the IRB Barcelona researcher has received funding from “La Marató”.

<p>Source: TV3</p>
10 Oct 2018

La Razón, TV3, La Sexta, Men's Health and New Atlas, among other local and international media, have published an article about the study done at IRB Barcelona and Vrije Universiteiti Brussel. The study has identified camelid nanobodies able to block EGF, a protein that is abundant in tumour cells and that helps them to proliferate.

Link to TV3

Link to...

<p>Figure showing the binding of a nanobody derived from alpaca to the EGF protein. The scientists demonstrate the high affinity and selectivity of a family of nanobodies for EGF, target of interest for the treatment of cancer (S Guardiola, IRB Barcelona)</p>
2 Oct 2018

A study done at IRB Barcelona and the Vrije Universiteit Brussel identifies camelid nanobodies able to block EGF, a protein that is abundant in tumour cells and that helps them to proliferate.

25 Sep 2018

The digital newspaper Público and other media have echoed a study headed by the Universitat Autònoma de Barcelona (UAB) and involving researchers from the Chemistry and Molecular Pharmacology Programme at IRB Barcelona that offers a promising advance towards a treatment for Parkinson’s disease,.

Published in the journal PNAS, the study has revealed that a small molecule, called SynuClean-D, disrupts the formation of amyloid fibers of alpha-synuclein—the process that triggers the development of Parkinson’s disease—and reverses the neurodegeneration that ensues.

Jesús Garcia, Salvador Guardiola, Ernest Giralt and Xavier Salvatella...

<p>The graphic shows a new class of prolyl oligopeptidase (POP) inhibitor. The inhibitor is able to reach the brain and bind to the POP protein, In yellow/red, the reactive group of the inhibitor that bind to the catalytic site of the protein (S Guardiola)</p>
17 May 2018

For the scientific community, the protein POP (prolyl oligopeptidase) is an attractive therapeutic target for the treatment of cognitive and neurodegenerative disorders.

Scientists at IRB Barcelona have developed the first POP inhibitors that are irreversible, selective and brain-permeable.

<p>Natàlia Carulla's team studies the associations of beta-amyloid. In the microscopy image, beta-amyloid clusters are observed in in vitro samples. (Bernat Serra-Vidal, IRB Barcelona)</p>
20 Apr 2018

Europa Press, El Economista, Technology Networks, News Medical, among other national and international media, have published an article about a study headed by IRB Barcelona that provides the first direct evidence of beta-amyloid dimers (two proteins joined together) in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers.

Link to Europa Press

Link to...

<p>Illustrative image of how scientists have deciphered the covalent nature of beta-amyloid dimers, an article published in Analytical Chemistry. Authors: Marina Gay, IRB Barcelona, and Lorena Markovich</p>
17 Apr 2018

A study headed by IRB Barcelona provides the first direct evidence of beta-amyloid dimers (two proteins joined together) in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers.

Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.

<p>Ernest Giralt</p>
14 Feb 2018

The Meet Our Scientists series presents Ernest Giralt, doctor of chemical sciences, who is the head of the Peptides and Proteins laboratory at IRB Barcelona.

In the video "The power of medicinal chemistry", Giralt highlights his interest in deciphering the language used by proteins to interact with each other.

<p>Image: Aydinlik</p>
23 Jan 2018

The Turkish media Aydinlik has published an article about the possibility of using poisons as medicine. The article includes a reference to the research on the use of bee venom as a strategy to selectively eliminate cancer cells, led by Ernest Giralt, leader of the Laboratory of Design, Synthesis and Structure of Peptides and Proteins of IRB Barcelona.

Link to Aydinlik

<p>Detail of one millimeter of a mouse brain. In green, capillaries that form part of the blood-brain barrier; in red, molecules attached to the shuttle patented by IRB Barcelona have managed to cross the barrier and reach the brain. (B Oller, IRB)</p>
9 Nov 2017

IRB Barcelona researcher Meritxell Teixidó has participated in the report "Menudes Teràpies" on the programme Quèquicom, broadcasted by Canal 33, There she talked about the advances made by the Design, Synthesis and Structure of Peptides and Proteins Lab, led by Ernest Giralt, regarding drugs with the capacity to overcome the blood-brain barrier and reach the brain.

Link to Menudes Teràpies

Link to additional clip